FibroGen Reports First Quarter 2018 Financial Results
May 09, 2018 16:02 ET
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
March 01, 2018 13:45 ET
|
FibroGen, Inc
SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
March 01, 2018 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
February 27, 2018 16:11 ET
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured...
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017
October 30, 2017 20:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quarter...
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
October 18, 2017 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
FibroGen Appoints Gerald Lema to Board of Directors
September 19, 2017 16:35 ET
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Gerald Lema, former President of Asia Pacific at...
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
September 05, 2017 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...
FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
August 07, 2017 16:50 ET
|
FibroGen, Inc.
Meets Primary Endpoint with Statistical Significance Management to discuss results on today’s quarterly financial results conference call SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen Reports Second Quarter 2017 Financial Results
August 07, 2017 16:38 ET
|
FibroGen, Inc.
Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Aug. 07, 2017 ...